Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy

Triona Ni Chonghaile, Kristopher A. Sarosiek, Thanh Trang Vo, Jeremy A. Ryan, Anupama Tammareddi, Victoria Del Gaizo Moore, Jing Deng, Kenneth C. Anderson, Paul Richardson, Yu Tzu Tai, Constantine S. Mitsiades, Ursula A. Matulonis, Ronny Drapkin, Richard Stone, Daniel J. DeAngelo, David J. McConkey, Stephen E. Sallan, Lewis Silverman, Michelle S. Hirsch, Daniel Ruben CarrascoAnthony Letai

Research output: Contribution to journalArticlepeer-review

Abstract

Cytotoxic chemotherapy targets elements common to all nucleated human cells, such as DNA and microtubules, yet it selectively kills tumor cells. Here we show that clinical response to these drugs correlates with, and may be partially governed by, the pretreatment proximity of tumor cell mitochondria to the apoptotic threshold, a property called mitochondrial priming. We used BH3 profiling to measure priming in tumor cells from patients with multiple myeloma, acute myelogenous and lymphoblastic leukemia, and ovarian cancer. This assay measures mitochondrial response to peptides derived from proapoptotic BH3 domains of proteins critical for death signaling to mitochondria. Patients with highly primed cancers exhibited superior clinical response to chemotherapy. In contrast, chemoresistant cancers and normal tissues were poorly primed. Manipulation of mitochondrial priming might enhance the efficacy of cytotoxic agents.

Original languageEnglish (US)
Pages (from-to)1129-1133
Number of pages5
JournalScience
Volume334
Issue number6059
DOIs
StatePublished - Nov 25 2011

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy'. Together they form a unique fingerprint.

Cite this